NF2 and central nervous system cancer: Further refinement of NF2 diagnostic criteria has been suggested following a recent study by Evans et al. in which nearly 3000 patients with molecular testing showed no evidence to support the inclusion of ‘glioma’ or ‘neurofibroma’ [44].